JP2024506041A - 潰瘍性大腸炎を予防、処置、または改善するためのアミセリモド - Google Patents

潰瘍性大腸炎を予防、処置、または改善するためのアミセリモド Download PDF

Info

Publication number
JP2024506041A
JP2024506041A JP2023547694A JP2023547694A JP2024506041A JP 2024506041 A JP2024506041 A JP 2024506041A JP 2023547694 A JP2023547694 A JP 2023547694A JP 2023547694 A JP2023547694 A JP 2023547694A JP 2024506041 A JP2024506041 A JP 2024506041A
Authority
JP
Japan
Prior art keywords
dose
subject
administering
amicelimod
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023547694A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506041A5 (https=
Inventor
ジミン イ
ニール スラトキン
エズラ アール． ロウ
ジーブ ハイマンソン
Original Assignee
ボシュ ヘルス アイルランド リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ボシュ ヘルス アイルランド リミテッド filed Critical ボシュ ヘルス アイルランド リミテッド
Publication of JP2024506041A publication Critical patent/JP2024506041A/ja
Publication of JP2024506041A5 publication Critical patent/JP2024506041A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Luminescent Compositions (AREA)
  • Cereal-Derived Products (AREA)
JP2023547694A 2021-02-08 2022-02-08 潰瘍性大腸炎を予防、処置、または改善するためのアミセリモド Pending JP2024506041A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163147060P 2021-02-08 2021-02-08
US63/147,060 2021-02-08
PCT/EP2022/053030 WO2022167690A1 (en) 2021-02-08 2022-02-08 Amiselimod for preventing, treating, or ameliorating ulcerative colitis

Publications (2)

Publication Number Publication Date
JP2024506041A true JP2024506041A (ja) 2024-02-08
JP2024506041A5 JP2024506041A5 (https=) 2025-02-14

Family

ID=80447376

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547694A Pending JP2024506041A (ja) 2021-02-08 2022-02-08 潰瘍性大腸炎を予防、処置、または改善するためのアミセリモド

Country Status (9)

Country Link
US (1) US20240299318A1 (https=)
EP (1) EP4288041A1 (https=)
JP (1) JP2024506041A (https=)
CN (1) CN116940350A (https=)
AU (1) AU2022217475A1 (https=)
CA (1) CA3207440A1 (https=)
MX (1) MX2023009249A (https=)
TW (1) TW202245742A (https=)
WO (1) WO2022167690A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025134072A1 (en) * 2023-12-21 2025-06-26 Bausch Health Ireland Limited Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017533895A (ja) * 2014-10-01 2017-11-16 レスピバート・リミテツド Ｐ３８キナーゼ阻害剤としての４−（４−（４−フェニルウレイドナフタレン−１−イル）オキシピリジン−２−イル）アミノ安息香酸誘導体
JP2018527406A (ja) * 2015-08-11 2018-09-20 アカール ファーマ ピーティーワイ リミテッドＡｋａａｌ Ｐｈａｒｍａ Ｐｔｙ Ｌｔｄ Ｓ１ｐ受容体モジュレーターを含む組成物
WO2020051568A1 (en) * 2018-09-08 2020-03-12 Wen Tan NEW USE OF R-ENANTIOMER OF ADRENERGIC β2 RECEPTOR AGONISTS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE AND ITS EXTRA INTESTINAL MANIFESTATIONS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
BRPI0619894B8 (pt) 2005-12-15 2021-05-25 Mitsubishi Tanabe Pharma Corp composto de amina e composição farmacêutica
JP5657565B2 (ja) 2008-12-22 2015-01-21 ノバルティス アーゲー Ｓ１ｐ受容体アゴニストの投与レジメン
PL3242666T3 (pl) * 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017533895A (ja) * 2014-10-01 2017-11-16 レスピバート・リミテツド Ｐ３８キナーゼ阻害剤としての４−（４−（４−フェニルウレイドナフタレン−１−イル）オキシピリジン−２−イル）アミノ安息香酸誘導体
JP2018527406A (ja) * 2015-08-11 2018-09-20 アカール ファーマ ピーティーワイ リミテッドＡｋａａｌ Ｐｈａｒｍａ Ｐｔｙ Ｌｔｄ Ｓ１ｐ受容体モジュレーターを含む組成物
WO2020051568A1 (en) * 2018-09-08 2020-03-12 Wen Tan NEW USE OF R-ENANTIOMER OF ADRENERGIC β2 RECEPTOR AGONISTS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE AND ITS EXTRA INTESTINAL MANIFESTATIONS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHIMANO, K. ET AL.: "Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 functional antagonist, inhibits pro", PLOS ONE, vol. 14, no. 12, JPN6025053778, 2019, pages 1 - 12, ISSN: 0005765829 *

Also Published As

Publication number Publication date
EP4288041A1 (en) 2023-12-13
CN116940350A (zh) 2023-10-24
CA3207440A1 (en) 2022-08-11
TW202245742A (zh) 2022-12-01
WO2022167690A1 (en) 2022-08-11
AU2022217475A1 (en) 2023-08-24
MX2023009249A (es) 2023-10-23
US20240299318A1 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
JP4938905B2 (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
CN106456626B (zh) 喹啉衍生物用于治疗软组织肉瘤的方法和用途以及用于治疗软组织肉瘤的药物组合物
JP6309454B2 (ja) 癌の併用処置
JP6244497B1 (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
US20230218596A1 (en) Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection
CA2872541A1 (en) Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
AU2015315628A1 (en) Use of reslizumab to treat moderate to severe eosinophilic asthma
KR20200062241A (ko) 시포니모드의 투여 요법
JP2024506041A (ja) 潰瘍性大腸炎を予防、処置、または改善するためのアミセリモド
JP2025106329A (ja) ベンラリズマブを使用した強化された患者個体群における慢性閉塞性肺疾患を治療するための方法
CN115038447A (zh) 用于治疗癌症的组合疗法
TW202042810A (zh) 一種含cdk4/6抑制劑的組合物與阿那曲唑聯合在製備治療腫瘤疾病的藥物中的用途
HK40094222A (zh) 预防、治疗或改善溃疡性结肠炎的阿米莫德
EA051860B1 (ru) Способ профилактики, лечения или облегчения язвенного колита
WO2025134072A1 (en) Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod
JP2025505187A (ja) 体重減少の方法および骨格筋量を保存する方法
WO2021224494A1 (en) New treatments of viral infections
CN110325214A (zh) 用于预防和治疗神经元损伤的低剂量药物组合
KR20220074913A (ko) S1p1 수용체와 관련된 상태를 치료하는 방법
WO2024104290A1 (en) Method for treating multiple sclerosis
Home Highlights in Ulcerative Colitis From the 18th Congress of ECCO
RU2672555C2 (ru) Комбинация ингибитора pi3 киназы с паклитакселом для использования при лечении или предотвращении рака головы и шеи
WO2022179592A1 (zh) 一种急性髓系白血病的联合治疗药物
TW202539668A (zh) 使用索樂匹尼布處置免疫性血小板減少症的方法
TW202525278A (zh) 治療慢性腎病及高血壓之方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250205

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260403